Aptamer Group PLC said on Wednesday that it has partnered with Neuro-Bio Ltd and declared success in the development of a lateral flow test to diagnose early Alzheimer’s disease.

The York, England-based company develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics, and research applications. Aptamer said it and its partner Neuro-Bio has successfully developed a panel of Optimer binders to a new Alzheimer’s disease biomarker.

Neuro-Bio is an Oxford, England-based biotech company with a therapeutic focus on neurodegenerative disease.

The partners plan to integrate binders into a routine lateral flow test, supporting clinical and commercial development of rapid diagnostics for Alzheimer’s disease through nasal sampling; possibly diagnosing the disease 10 to 20 years before symptoms emerge.

Interim Chief Executive Officer Rob Quinn said: ‘With an increasingly ageing population and no current tests available for early-stage diagnosis, the advancement of new biomarking and diagnostics in this field offers hope to millions of patients and their loved ones worldwide.’

Aptamer shares jumped to 22.50 pence on Wednesday in London, rising sharply from Tuesday’s closing price of 10.00 pence each.

Copyright 2023 Alliance News Ltd. All Rights Reserved.